LifeMax is a privately held, clinical stage biotech company focused on developing first-in-class or best-in-class therapeutics for orphan diseases that have few or no therapeutics options. We have three clinical stage programs, LM-030, AMB-051 and AMB-053, with the lead program, LM-030, ready to enter into a pivotal trial.
Through in-licensing from either big pharma/biotech companies or academic institutions, we have established a robust and science-driven portfolio that targets the underlying causes of the various orphan diseases with few or no approved therapeutic options. Our focus is on first-in-class or best-in-class therapeutics that will truly bring meaningful and/or life-saving benefits to patients. We are also leveraging sponsored collaboration and research with universities to help de-risk potential projects before their adoption into our pipeline.